Drugs / GSK217744
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01453998 | Oct 2011 → Nov 2012 | diphtheria, haemophilus infectious disease, hepatitis B virus infection, poliomyelitis +1 | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT01248884 | Dec 2010 → Jan 2012 | diphtheria, haemophilus infectious disease, hepatitis B virus infection, poliomyelitis +1 | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GSK217744 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01248884 ↗ |
| Modality | Vaccine | “GSK217744 formulation A vaccine” NCT01248884 ↗ |
| Route | Intramuscular | “The GSK217744 and Prevenar 13® vaccines were administered intramuscularly” NCT01248884 ↗ |